Seems like a lot of volume for the early part of the trading day - holding well. lewes
lewes, congrad with ECYT.<Endocyte to Get $120 Mln in Upfront Payment for Pact with Merck> This is the price for Ph III in progress.ARQL got almost nothing making the deal during PhII. ARQL management is NOT good at raising money.I wish they make a deal on their non-partnered pipeline outside from Jap partners.Pharma
Over 1.2M shares traded with 2 block of 77.5k and 372K shares traded after closing.Somebody knows something!
I agree - but maybe they are seeing the light.Cash value of ecyt was 3.50 so a good trade they had to go up with good news. regards, lewes